Pelthos Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Pelthos Therapeutics Inc. (PTHS)
Company Research
Source: GlobeNewswire
DURHAM, N.C., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced that its CEO, Scott Plesha, will present at the Oppenheimer 36th Annual Healthcare Life Sciences conference on February 26, 2026 at 10:00 a.m. Eastern Time. The Pelthos management team is scheduled to host one-on-one meetings with investors and attendees during the conference. Investors interested in arranging one-on-one meetings should contact their Oppenheimer representative. The webcast of Mr. Plesha’s presentation will be available at: https://event.summitcast.com/view/CTtthLh2Bi2D9aYoKpvtEv/J9Koj4G9CNA2FTUisjSEq8 The presentation will also be located under “News & Events” in the Investors section of the Company’s website at www.pelthos.com. A replay of the webcast will be available on the Pelthos’ website for 90 days following the presenta
Show less
Read more
Impact Snapshot
Event Time:
PTHS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTHS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTHS alerts
High impacting Pelthos Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
PTHS
News
- Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology FinanceGlobeNewswire
- Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice [Yahoo! Finance]Yahoo! Finance
- Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head LiceGlobeNewswire
- Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew EinhornGlobeNewswire
- Ligand Pharmaceuticals Incorporated (LGND) Analyst/Investor Day Transcript [Seeking Alpha]Seeking Alpha
PTHS
Earnings
- 11/13/25 - Miss
PTHS
Sec Filings
- 2/17/26 - Form SCHEDULE
- 2/13/26 - Form 424B3
- 2/10/26 - Form EFFECT
- PTHS's page on the SEC website